Geode Capital Management LLC Has $225,000 Holdings in IGC Pharma, Inc. (NYSEMKT:IGC)

Posted by Defense World Staff on May 4th, 2025

Geode Capital Management LLC boosted its position in shares of IGC Pharma, Inc. (NYSEMKT:IGC – Free Report) by 19.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 669,685 shares of the company’s stock after acquiring an additional 106,716 shares during the period. Geode Capital Management LLC owned 0.86% of IGC Pharma worth $225,000 at the end of the most recent quarter.

Separately, Virtu Financial LLC raised its stake in IGC Pharma by 164.7% during the 3rd quarter. Virtu Financial LLC now owns 123,060 shares of the company’s stock valued at $53,000 after purchasing an additional 76,563 shares during the last quarter. 3.87% of the stock is owned by institutional investors and hedge funds.

IGC Pharma Price Performance

IGC Pharma stock opened at $0.30 on Friday. The business’s 50-day simple moving average is $0.30 and its 200 day simple moving average is $0.33. The company has a quick ratio of 0.98, a current ratio of 1.15 and a debt-to-equity ratio of 0.02. The stock has a market cap of $24.22 million, a price-to-earnings ratio of -2.76 and a beta of 1.45. IGC Pharma, Inc. has a 12-month low of $0.25 and a 12-month high of $0.62.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on IGC. Ascendiant Capital Markets lifted their price target on shares of IGC Pharma from $4.00 to $4.25 and gave the stock a “buy” rating in a research note on Monday, February 24th. Alliance Global Partners reiterated a “buy” rating and set a $3.50 target price on shares of IGC Pharma in a research report on Thursday, March 6th.

Check Out Our Latest Stock Analysis on IGC Pharma

IGC Pharma Company Profile

(Free Report)

IGC Pharma, Inc, a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development.